Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

b site is http://www.schering-plough.com.

SCHERING-PLOUGH CORPORATION

U.S. GAAP report for the fourth quarter ended December 31 (unaudited):

(Amounts in millions, except per share figures)

Fourth Quarter Full Year

2007 2006 2007 2006

Net sales 1/ $3,724 $2,650 $12,690 $10,594

Cost of sales 2/ 1,566 915 4,405 3,697

Selling, general

and administrative 1,634 1,250 5,468 4,718

Research and

development 3/ 855 631 2,926 2,188

Acquired in-process

research and

development 4/ 3,754 - 3,754 -

Other income, net 5/ (231) (46) (683) (135)

Special and acquisition

related charges 6/ 52 12 84 102

Equity income (566) (403) (2,049) (1,459)

(Loss)/income before

income taxes (3,340) 291 (1,215) 1,483

Income tax (benefit)/

expense (14) 87 258 362

Net (loss)/income

before cumulative

effect of a change

in accounting

principle $(3,326) $204 $(1,473) $ 1,121

Cumulative effect

of a change in

accounting principle,

net of tax 7/ - - - (22)

Net (loss)/income $(3,326) $204 $(1,473) $ 1,143

Preferred stock

dividends 38 22 118 86

Net (loss)/

income available

to common

shareholders $(3,364) $
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), an...r to its shareholders, discussing the Company,s ac...ceuticals Holdings, Inc. (CHBP), an integrated bio...blic of China. The merger gives NeoStem a controll... Ltd., CHBP,s primary operating subsidiary and a p...
(Date:11/19/2009)...ber 19 MONITORING FORCE GmbH,annou...libanserin in the,indication treatment-relevant le...or orphan drug status designation with the Europea...esia is a complication of the mainstay,treatment i...e of those,affected, since it may be disabling for...
(Date:11/19/2009)...e Synthesis Companies Form International Gene Synt...es in Risk Reduction ,Five Member Companies Repr...ity , (PRWEB) November 19...ynthesis companies today announced agreement that ...mote biosecurity in the gene synthesis industry. ...
(Date:11/18/2009)...ire/ -- Marrone Bio Innovations (MBI), a leader in...of effective and environmentally responsible pest ...med an IC20 company by the Investors, Circle, the ...nvesting group. ,, Companies named to the IC20 ...for all stakeholders, including investors, the env...
Breaking Biology Technology:NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4Marrone Bio Innovations Named an IC20 Company 2
...- Oncothyreon Inc. (NASDAQ:,ONTY) (TSX: ONY) (the ...o,focus the Company,s resources on the clinical de...lopment and manufacturing of Stimuvax(R).,Oncothyr...opment of PX-12,beyond the ongoing trials. The pri...yreon,s efforts and available resources on those p...
...ics,Inc. (Nasdaq: CVTX ) announced today that the... 1 trial of CVT-3619, a novel oral compound for po... U.S. Food and Drug,Administration recently accept...ion for CVT-3619, a partial A1 adenosine receptor ...ty and pharmacokinetic profile,of CVT-3619 in heal...
...rdue patents; Purdue licenses limited sa..., Conn., Sept. 2 Purdue Pharma L.P. of,Stamford, ...ssouri have,agreed to end the OxyContin(R) (oxycod...ement lawsuit between them in the United States Di...., According to the agreement, Mallinckrodt ackno...
Other Biology Technology:Oncothyreon announces prioritization plan for development programs 2Oncothyreon announces prioritization plan for development programs 3Oncothyreon announces prioritization plan for development programs 4Oncothyreon announces prioritization plan for development programs 5CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases 2CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases 3Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc. 2
(Date:11/20/2009)...mber 19th 2009 - Bacteria possess an ingenious mec...ding blocks of the cell. This is the new finding o... of VIB, a life sciences research institute in Fla...t Brussel. The scientists made this discovery by m...erichia coli . By means of this model organism, th...
(Date:11/20/2009)...l. In a new study, researchers report that a clas...ve a helpful, or harmful, effect on the heart, dep... which appears in the journal Circulation Researc...alpha- and beta-receptors on the heart muscle offe...e that target only the beta-receptors can actually...
(Date:11/19/2009)...mportant crop in many countries of the world. It i...and industrial materials. It also is considered an..., molecular evolution, and genome architecture. Th...l collection used the first description of the B73... questions in genetics and plant biology. The ten ...
Breaking Biology News(10 mins):Biologists discover bacterial defense mechanism against aggressive oxygen 2Carvedilol shown to have unique characteristics among beta blockers 2PLoS Genetics 2009 maize genome collection 2PLoS Genetics 2009 maize genome collection 3PLoS Genetics 2009 maize genome collection 4Mars Veterinary Offers New Insights Into Mixed Breed Dogs 57197 1Mars Veterinary Offers New Insights Into Mixed Breed Dogs 57197 2Mars Veterinary Offers New Insights Into Mixed Breed Dogs 57197 3Canadian researchers discover the first ever link between intelligence and curiosity 57194 1Canadian researchers discover the first ever link between intelligence and curiosity 57194 2Accumetrics Inc Announces Endotech SPA as Exclusive Distributor for the VerifyNow System in Italy 57191 1Accumetrics Inc Announces Endotech SPA as Exclusive Distributor for the VerifyNow System in Italy 57191 2
...the gypsy moth range may help to slow their invasi...esearchers. , "Slowing the spread of the gypsy mot... says Ottar Bjornstad, associate professor of ento...e underlying patterns in the spread of invasive sp... The accidental release of the gypsy moth in 1869 ...
...g a worldwide research project which could revolut... children in developing countries. , The four-year...ed in four hospitals in India, will offer a means ...sease quickly, cheaply and with little training ne... improving children,s health could be enormous. ...
...her suggests a new avenue for developing a vaccine...by herpes simplex viruses. , In a study published...rologist William Halford showed that mice vaccinat...x virus type 1 (HSV-1) showed no signs of disease ...al "wild-type" strain of the virus. , In contras...
Other Biology News:Edge density key to controlling gypsy moth spread 2Hope for major advance in fighting world killer disease 2Hope for major advance in fighting world killer disease 3Research holds promise for herpes vaccine 2
Cleland’s Reagent, ULTROL® Grade from Calbiochem
...icroarray is specifically designed for location an... pairing chromatin immunoprecipitation (ChIP) with... hybridization and reliable binding data with grea... In addition, Agilent provides flexibility by offe...
...mes has allowed the development of the S. enterica...rica Typhimurium (strain LT2) genome consists of a...a plasmid, pSLT (93,939 bp; 107 ORFs). These ORFme...y all putative open reading frames (ORFs) in S. en...
...system, offers fast and reliable batch processing ...lution , SAFIRE monochromator reader , GENios fami...s of Laser Scanners , Powerwash 384 ,By supporti...s, Connect offers researchers increased throughput...
Biology Products: